Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea? Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?

ORIGINAL ARTCLE

Rev Bras Cir Cardiovasc 2009; 24(3): 373-381

Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass? Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

Cesar Augusto FERREIRA1, Walter Villela de Andrade VICENTE2, Paulo Roberto Barbosa ÉVORA3, Alfredo José RODRIGUES4, Jyrson Guilherme KLAMT5, Ana Paula de Carvalho Panzeli CARLOTTI6, Fábio CARMONA7, Paulo Henrique MANSO8

RBCCV 44205-1103 Abstract Objective: Evaluation of the hemostatic and platelets effects in children with acyanogenic congenital heart disease undergone on-pump surgery who received aprotinin. Methods: A prospective randomized study was performed on children aged 30 days to 4 years who had undergone correction of acyanogenic congenital heart disease using cardiopulmonary bypass (CPB) and were divided into two groups: Control (n=9) and Aprotinin (n=10). In the Aprotinin Group the drug was administered before and during CPB and the hemostatic dysfunction was analyzed by clinical

and biochemical markers. Differences were considered to be significant when P